Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.

@article{Hauber2011EconomicEO,
  title={Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.},
  author={A. Brett Hauber and Jochen Fleischmann and Mickael Lothgren and Michele Wilson and Annette Lam and Dominique Dubois and Rainer Sabatowski},
  journal={Journal of opioid management},
  year={2011},
  volume={7 4},
  pages={287-96}
}
OBJECTIVES OROS hydromorphone (osmotic extended-release oral delivery system [OROS] hydromorphone) is a long-acting opioid analgesic, which is approved in Europe for the management of severe pain. The authors aimed to estimate the economic value of this product relative to other widely used oral opioids, including sustained-release morphine, extended-release (ER) oxycodone, and twice-daily (bid) hydromorphone. DESIGN An adaptable, decision-analytic cost-utility model was developed. Separate… CONTINUE READING